A Phase 2 interventional study of Paclitaxel in Head and Neck Cancer, sponsored by Bristol-Myers Squibb. Completed at 9 sites in Japan. Per ClinicalTrials.gov, last updated 2022-04-08.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing paclitaxel in Head and Neck Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. Paclitaxel · Head and Neck Neoplasms.
Among the 61 studies testing paclitaxel in Head and Neck Neoplasms, this one is the 51st largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2006, is one of 43 in phase 2, and was the 36th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →8 of the 61 studies testing paclitaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
Barbara Ann Karmanos Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 48 · Phase 3 4
First in 1988; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 40 across the 55 interventional studies. Of the 43 that completed or were terminated, 17 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 61 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb: 1 open now, 1 under way, none of them phase 3. Of 16 finished, 4 (25%) have results posted.
Among the 18 studies in Head and Neck Neoplasms by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2006, is one of 5 in phase 2, and was the 4th registered.
Bristol-Myers Squibb’s Head and Neck Neoplasms studies by the year they started, since 2004.
3 of the studies testing paclitaxel in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05420948University of ChicagoA Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer | 2026-12-01 |
| NCT06793761Beijing Tongren HospitalA Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC | 2026-12-20 |
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 61 studies testing paclitaxel in Head and Neck Neoplasms, from their registry updates:
Among Bristol-Myers Squibb’s 18 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects
Inclusion Criteria:
Drug: Paclitaxel
Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
Also known as: Taxol, BMS-181339
Number of Participants With SAEs
Number of Participants with SAEs
Time frame: From the first infusion to the completion of study. Approximately up to 28 months
Number of Participants With Adverse Events Leading to Discontinuation
Number of Participants with Adverse Events Leading to Discontinuation
Time frame: From the first infusion to the completion of study. Approximately up to 28 months
Number of Participants With Adverse Events
Number of Participants with Adverse Events
Time frame: From the first infusion to the completion of study. Approximately up to 28 months
Number of Participants With Laboratory Abnormalities
Number of Participants with Laboratory Abnormalities
Time frame: From the first infusion to the completion of study. Approximately up to 28 months
Number of Participants With Drug Related Laboratory Abnormalities
Number of Participants with Drug Related Laboratory Abnormalities
Time frame: From the first infusion to the completion of study. Approximately up to 28 months
Number of Participants With Best Overall Response Per RECIST Criteria
Best overall response is represented by the number participants who have had complete response, partial response and have stable disease.
Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Number of Participants With Best Overall Response Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer
Best overall response is represented by the number participants who have had complete response, partial response and not completed.
Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Duration of Overall Response as Per RECIST Criteria
DOR is defined as the median time from the first date of Partial Response to the first date of Progressive Disease. Participants were evaluated for DOR in a separate study (NCT00971867).
Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Duration of Overall Response as Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer
Best overall response is represented by the number participants who have had complete response, partial response and not completed.
Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
| Milestone | Paclitaxel |
|---|---|
| Started | 11 |
| Completed | 0 |
| Not completed | 11 |
| Withdrew: Adverse event | 4 |
| Withdrew: Participant withdrew consent | 1 |
| Withdrew: Disease progression | 6 |
Number of Participants with SAEs
| Number of Participants | Paclitaxel |
|---|---|
| Number of Participants With SAEs | 3 |
Number of Participants with Adverse Events Leading to Discontinuation
| Number of Participants | Paclitaxel |
|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation | 5 |
Number of Participants with Adverse Events
| Number of Participants | Paclitaxel |
|---|---|
| Number of Participants With Adverse Events | 11 |
Number of Participants with Laboratory Abnormalities
| Number of Participants | Paclitaxel |
|---|---|
| Number of Participants With Laboratory Abnormalities | 11 |
Number of Participants with Drug Related Laboratory Abnormalities
| Number of Participants | Paclitaxel |
|---|---|
| Number of Participants With Drug Related Laboratory Abnormalities | 11 |
Best overall response is represented by the number participants who have had complete response, partial response and have stable disease.
| Number of Participants | Paclitaxel |
|---|---|
| Complete Response (CR) | 1 |
| Partial Response (PR) | 6 |
| Stable Disease (SD) | 4 |
Best overall response is represented by the number participants who have had complete response, partial response and not completed.
| Number of Participants | Paclitaxel |
|---|---|
| Complete Response (CR) | 1 |
| Partial Response (PR) | 9 |
| Not Completed | 1 |
DOR is defined as the median time from the first date of Partial Response to the first date of Progressive Disease. Participants were evaluated for DOR in a separate study (NCT00971867).
| Days | Paclitaxel |
|---|---|
| Duration of Overall Response as Per RECIST Criteria | 222 (70 to 847) |
Best overall response is represented by the number participants who have had complete response, partial response and not completed.
| Days | Paclitaxel |
|---|---|
| Duration of Overall Response as Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer | 269 (140 to 904) |
Collected over From the first infusion to the completion of study. Approximately up to 28 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paclitaxel | 0/11 (0%) | 3/11 (27.3%) | 11/11 (100%) |
| Event | Paclitaxel |
|---|---|
| Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders | 1/11 |
| VomittingGastrointestinal disorders | 1/11 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/11 |
| Cancer PainGeneral disorders | 1/11 |
| Event | Paclitaxel |
|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 11/11 |
| HypoesthesiaNervous system disorders | 9/11 |
| FatigueGeneral disorders | 7/11 |
| Weight DisorderGeneral disorders | 5/11 |
| Nail DisorderGeneral disorders | 5/11 |
| Age, Categorical(Participants) | Paclitaxel |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 4 |
| Sex: Female, Male(Participants) | Paclitaxel |
|---|---|
| Female | 2 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | Paclitaxel |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 11 |
| Race (NIH/OMB)(Participants) | Paclitaxel |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 11 |
Ran from Aug 2006 to primary completion in Nov 2008, 27 months.
Results were first posted in Apr 2022, 13 years 4 months after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 27 months is below that.
Counting every sponsor, half of 260 studies reached it within 51 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel